BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 3, 2006--Tercica, Inc. (Nasdaq:TRCA) today announced the U.S. commercial launch of Increlex(TM) (mecasermin (rDNA origin) injection), the only recombinant human insulin-like growth factor-1 (rhIGF-1) replacement therapy indicated for the long-term treatment of growth failure in children with severe Primary IGFD. Tercica also announced that following its December 2005 submission for marketing approval in the EU, the company is preparing for a potential January 2007 launch of Increlex in Europe. Increlex, which is now available to patients throughout the U.S., represents the first major innovation in treating children with short stature since recombinant human growth hormone was approved 20 years ago.
